

**Mexico City, July 16, 2021** – MEDICA, S.A.B. de C.V. (“Medica Sur”, “MÉDICA”, “MS”, or “the “Company”) (BMV ticker symbols: MEDICAB and CEBURES MEDICA 20) reports its unaudited results corresponding to the second quarter of 2021 (2Q21). This information is being presented in accordance with International Financial Information Reporting Standards (“IFRS”).

## **Relevant 2Q21 events:**

### ***Present Situation***

In our country and in Mexico City the effects of the pandemic still persist to a significant degree, since only 26% of the adult population has been completely vaccinated against the COVID-19 virus.<sup>1</sup>

At the beginning of the second quarter the Company observed a decline in the number of patients being treated for Covid-19. However, the number of patients began to increase again toward the month of June, and that trend has continued up to the time of issuance of this report.

In Médica Sur we feel confident and prepared to continue to treat COVID and non-COVID patients in a safe and simultaneous manner. We have the experience, the best infrastructure, and the specialized personnel. We have had outstanding results in the safety standards for our patients, our collaborators and our visitors, while always delivering the best possible treatment.

Since the beginning of the pandemic in March of 2020, we have processed more than 700 thousand tests and treated and discharged to home more than 1,600 COVID patients.

### ***40 years***

In the month of June we celebrated 40 years of offering the best hospital services in Mexico. We will continue to work with constancy and perseverance in our fervid determination to serve our patients, who are the most important reason for our existence. We feel deep satisfaction in being the leaders in medical attention in Mexico, in the warmth with which we treat our patients, and in being in the technological vanguard of medicine in this country.

### ***Results***

The first half of 2021 showed a significant recovery in hospital services in all the previous months of the year. During 2Q21 we treated and discharged to home 3,158 patients, 62.0% more than in 2Q20.

- The Company’s revenues in that quarter reached MXN 1,389 million, an increase of 65.8% compared to 2Q20. This increase was driven mainly by the following three factors:
  - i) The recovery in non-COVID services. The scheduling of outpatient and inpatient surgeries increased markedly, inclusively surpassing the pre-pandemic levels of the year 2019.
  - ii) Added to the above was the recovery in clinical and diagnostic services, such as the Oncological Center, Radiotherapy, Neurophysiology, Advanced Urology and Radiosurgery.
  - iii) We continued with our treatment of hospitalized COVID patients and the processing of tests for the detection of the virus, follow-up treatments and the tests to measure antibody levels after vaccinations and recovery.

In the second quarter, the company reached 123 diagnosis and treatment branches, 40 of them exclusively for COVID tests.

- The operating income for 2Q21 grew by 233.5% compared to 2Q20, reaching MXN 299.6 million. The operating margin improved by 10.8 percentage points, reaching 21.6% at the end of the second quarter of 2021, thanks to the increased revenue mentioned above and to the Company’s strict management of its costs and expenses.

- The company's EBITDA was MXN 381.0 million in 2Q21, which represents a growth of 120.3% compared against the same period in the previous year. At the same time the EBITDA margin had a positive effect, growing from 20.6% in 2Q20 to 27.4% at the end of 2Q21.
- As for net income, Médica Sur obtained outstanding results compared to the same period of the previous year, which it has maintained since the end of 2020. In the quarter, the net income was MXN 191.4 million, which represents a growth of 334.5%. The net margin grew by 8.5 percentage points to 13.8%.

### Médica Sur, S.A.B. de C.V. and Subsidiaries

#### Unaudited results

	2Q20	2Q21	Change \$	Change %
<b>Revenues</b>	<b>837.9</b>	<b>1,389.7</b>	<b>551.7</b>	<b>65.8%</b>
<b>Operating Income</b>	<b>89.8</b>	<b>299.6</b>	<b>209.7</b>	<b>233.5%</b>
Operating Margin	10.7%	21.6%		10.8 bps
<b>EBITDA*</b>	<b>173.0</b>	<b>381.0</b>	<b>208.0</b>	<b>120.3%</b>
EBITDA Margin	20.6%	27.4%		6.8 bps
<b>Net Consolidated Income</b>	<b>44.0</b>	<b>191.4</b>	<b>147.3</b>	<b>334.5%</b>
Net Margin	5.3%	13.8%		8.5 bps

Amounts in million pesos. Includes rounding effects.

- On the date of issuance of this report, Médica Sur is in compliance with all its financial obligations. The Company continues to operate normally, observing a considerable recovery in some areas, with volumes of operation that had diminished in the past, such as in the diagnostics and elective surgery departments. We expect this positive trend to continue, with a slow recovery as the vaccination process advances and the COVID-19 pandemic landscape improves. The Company has had an excellent generation of cash flow with which to face its operational and payments obligations in the months ahead.

<sup>(1)</sup> Source: Report from the Secretariat of Health up to 06/22/21.

## Relevant 2Q21 Data

### Volume and indicators

- During 2Q21 Médica Sur enjoyed the confidence of 3,158 patients who were hospitalized and discharged to home, an increase of 62% over the same period in the preceding year.
- In the second quarter the company reached 123 diagnostic and treatment branches, 40 of them exclusively for COVID tests. The Company's geographic presence increased from 6 to 14 cities, from the installation of units in Grupo Aeroportuario del Pacífico (GAP) airports, announced by the Company in the first quarter of 2021.
- As previously mentioned, we observed a significant recovery in non-COVID procedures, which, in conjunction with the COVID-19 patients, resulted in very favorable financial results.
- The average stay of non-COVID patients increased marginally, growing from 3.48 to 3.74 days, representing an increase of 7.4% above the second quarter of 2020.
- On the other hand, the average stay of non-critical COVID patients decreased from 7.20 to 6.19 days, 14.1% lower than 2Q20. The hospitalization time of critical COVID patients also decreased, going from 16.81 to 14.15 days, a decrease of 15.8%.

## Main Hospital Achievements in 2Q21:

- **Médica Sur completes 40 years in operation.**

In the month of June of 2021, we celebrated our 40th anniversary with great pride and satisfaction. Ever since its foundation, Médica Sur has had as its goal to be a highly specialized, cost-effective, private medical center, complying with international standards of efficiency, sustainability and Ethics. In Médica Sur we have gathered a group of medical, nursing, administration and hospital operation professionals, all of whom have as an objective to deliver a service of medical excellence and human warmth, guided by a strict code of ethics and supported by medical equipment and infrastructure with leading edge technology. After 40 years of offering the best hospital services In Mexico, we can affirm that nothing can hold us back. We will continue with our constancy and perseverance and with our goal of serving our patients, which is the primary object of our existence. We are happy to be the leaders in medical services, in the human warmth we show to our patient, and in our leading-edge technology.



- **Our ranking in Expansion Magazine's list of the "500 Most Important Companies in Mexico" went up by 34 places.**

We are proud to share that in the 2021 April edition of Expansion Magazine we advanced 34 places from our position the previous year in the ranking of "The 500 Most Important Companies in Mexico." This ranking is established by the said publication based on various factors, such as corporate integrity policies (IC500 Index), sales and income, financial indicators, actions taken against the pandemic, and other factors.



- **COVID Services:**

In our country and in Mexico City the effects of the pandemic still linger to a significant degree, since only 26% of the adult population of Mexico City has been completely immunized against the COVID-19 virus<sup>(1)</sup>



At the beginning of 2021 the Company observed a declining incidence in the treatment of patients hospitalized because of COVID-19. However, the number of patients hospitalized for that reason began to rise again in June, and the increase has continued up to the day of release of this report.

We feel confident and prepared to continue to treat COVID and non-COVID patients in a safe and simultaneous manner. We have the experience, the best infrastructure, and the specialized personnel. We have had outstanding results in the safety standards for our patients, our collaborators and our visitors, always delivering the best possible treatment.

Since the beginning of the pandemic in March of 2020, we have processed more than 700 thousand tests and treated and discharged to home more than 1,600 COVID patients.

**+1,600**  
**COVID patients**  
**treated**

**+700**  
**thousand**  
**Tests**  
**processed**

- **Renovation of our Magnetic Resonance Imaging service**

In Médica Sur we are creating innovations in order to deliver high-precision and quality medical treatment to our patients.

In April we renovated our Magnetic Resonance Imaging Service, incorporating the *Siemens MAGNETOM Sola Resonator*, with Biomatrix 1.5 Teslas technology, which utilizes a magnetic field and computer-generated radio waves to create detailed and precise images of the body's internal structures.

This equipment has movement-correction sensors in real time. It produces high-quality results without the need to repeat the studies, thus reducing the time needed for the acquisition of the images.

The technology offers several advantages, such as: greater comfort of the patient during the procedure, automatically adjusting to the patient's anatomy. It anticipates the patient's breathing, improving his/her experience of the procedure.

It incorporates shorter tunnels and an ample interior diameter, thus reducing the claustrophobic sensation.

We are proud to offer the better alternatives to our patients, with equipment of the most advanced technology.





- **Médica Sur is a proud sponsor of the Mexican Olympic Committee**

In Médica Sur we are well aware that sports are an important factor in the creation of a better world. Because of that fact, we are a proud sponsor of the Mexican Olympic Committee that will attend the Tokyo Olympic Games in 2020+1.

We will apply a total of 1,000 tests for the detection of the SARS-COV2 virus that will be carried out as an indispensable requirement before the arrival of the athletes in Tokyo.

The most important thing is to support our athletes so that they may concentrate only on doing their best for the glory of their country.

Laboratorio Médica Sur is the only laboratory authorized in Mexico by the Mexican Olympic Committee and by the Organizing Committee of the Tokyo Olympic Games of 2020 + 1.

We wish our athletes the best success.



- **Laboratorio Médico Polanco, official sponsor of #LaOlaParalímpica**

Our affiliate, Laboratorio Médico Polanco, is also a proud sponsor of the "Para-Olympic Wave," carrying out tests for the detection of the SARS-COV2 virus for the Mexican Athletic Open, to thereby offer our support to the health and wellbeing of our athletes.



- **Payment of dividends in the amount of MXN 1.50 per share.**

On April 29 of 2020, the Annual Ordinary General Shareholders Meeting decreed the payment of a cash dividend in the amount of MXN 1.50 per share, corresponding to the results of 2020, representing a total of MXN 169,790,794 payable beginning on May 21, 2021.

## 2Q21 Financial Summary

### • Revenues

The revenue for 2Q21 showed a rising tendency, which we have maintained since 4Q2020.

During 2Q21 we treated and discharged to home 3,158 patients from hospitalization, 62.0% more than in 2Q20.

The Company's revenues rose to MXN 1,389 million, an increase of 65.8% compared to 2Q20, driven by three principal factors:


i) The recovery of non-COVID services. The scheduling of outpatient and hospitalization surgeries increased significantly, inclusively surpassing the pre-pandemic levels seen in 2019.

ii) Added to the above was the recovery in clinical services and diagnostic units, such as: the Oncology, Radiotherapy, Neurophysiology, Advanced Urology and Radiosurgery centers.

iii) We continued with our treatment of hospitalized COVID patients, the processing of tests for the detection of the virus, and follow-up treatments and tests to measure antibody levels after vaccinations and recovery.

Since the beginning of the pandemic in March of 2020, we have processed more than 700 thousand tests and treated and discharged to home more than 1,600 COVID patients. Additionally, there was a considerable increase in the number of tests referred to us by other laboratories and companies.

Figures in million pesos




### • Operating income

The Company's operating income in 2Q21 grew by 233.5% compared to 2Q20, for a total of MXN 299.6 million.


The operating margin improved by 10.8 percentage points, reaching 21.6% at the end of the second quarter of 2021, thanks to the increase in revenue mentioned above and to the Company's strict management of costs and expenses.

Figures in million pesos



## • EBITDA

The Company's EBITDA stood at MXN 381.0 million in 2Q21, which represents a growth of 120.3% compared against the same period in the previous year. At the same time the EBITDA margin had a positive effect, growing from 20.6% in 2Q20 to 27.4% at the end of 2Q21.




## • Taxes

Taxes for 2Q21 were higher compared to the same period of the previous year, given the increase obtained in income for the period, as explained previously.

## • Net income

As for net income, Médica Sur recorded strong performance compared to the same period of the previous year, which has been maintained since the end of 2020. Net income totaled MXN 191.4 million, an increase of 334.5%. The net margin grew 8.5 percentage points reaching 13.8%.



- **Indebtedness and Comprehensive Cost of Financing (CCF)**

The Company's net debt decreased significantly by 92% from MXN 823.8 million in 2Q20 to MXN 66.1 million in 2Q2021, which was primarily derived from cash generation throughout the period.

	2Q20	2Q21	Change (MXN)	Change (%)
Debt	1,299.0	1,000.0	(299.0)	-94.9%
Cash	475.2	933.9	458.7	96.5%
<b>Net debt</b>	<b>823.8</b>	<b>66.1</b>	<b>(757.8)</b>	<b>-92.0%</b>

In regard to the CCF, interest paid decreased by MXN 10.9 million, mainly as the result of the lower financing cost of the MEDICA 20 debt certificates, compared to the bank credits that the Company had in 2Q20.

Interest earned increased by MXN 1.4 million, as the result of a greater cash position.

Thus, the CCF of 2Q21 was MXN 21.2 million, which had a favorable effect in the amount of MXN 12.3 million compared against 2Q20.

- **Stock Repurchasing Fund**

At the Annual Ordinary General Shareholders' Meeting held on April 29, 2020, the maximum approved amount of resources that may be used for the purchase of the Company's own shares during 2021 was MXN 500.0 million. In 2Q21, the issuer did not carry out any transactions through the repurchase fund.

## Financial Statements (unaudited) (amounts in MXN)

Médica Sur, S.A.B. de C.V.

### Balance Sheet as of December 31, 2020 and June 30, 2021

	<u>2020</u>	<u>2Q21</u>	<u>Change % YoY</u>	<u>Change \$ YoY</u>
<b>Assets</b>	6,279,160,876	6,667,749,245	6.2%	388,588,369
<b>Current assets</b>	1,618,245,570	2,083,189,262	28.7%	464,943,692
Cash and Cash Equivalents	572,844,050	933,947,284	63.0%	361,103,233
Restricted Cash	-	-	0.0%	-
Accounts Receivable	599,684,094	731,537,471	22.0%	131,853,377
Others Net Account Receivable	74,726,619	54,648,534	-26.9%	-20,078,084
Inventories	155,376,649	147,441,815	-5.1%	-7,934,834
Assets held for sale	215,614,158	215,614,158	0.0%	0
<b>Long Term</b>	-	-	0.0%	-
Accounts and Documents Receivable (Net)	-	-	-	-
Investments in Unconsolidated Subsidiaries and Associated Shares	-	-	-	-
Other Investments	-	-	-	-
<b>Property, Plant and Equipment (Net)</b>	3,065,861,480	2,993,449,353	-2.4%	-72,412,127
Property	2,751,967,535	2,755,198,114	0.1%	3,230,579
Industrial Machinery and Equipment	83,251,023	85,086,740	2.2%	1,835,717
Other Equipment	2,022,037,750	2,077,843,072	2.8%	55,805,321
Right-of-use asset	486,669,217	509,519,850	4.7%	22,850,633
Accumulated Depreciation	-2,196,840,454	-2,285,708,362	4.0%	-88,867,908
Accumulated Depreciation Right-of-use asset	-187,193,645	-236,138,730	26.1%	-48,945,085
Constructions in Process	105,970,055	87,648,671	-17.3%	-18,321,383
<b>Investment properties</b>	80,241,167	76,427,764	-4.8%	-3,813,403
Land	52,165,613	52,165,613	0.0%	0
Buildings	28,075,554	24,262,151	-13.6%	-3,813,403
<b>Intangible Assets</b>	1,514,812,659	1,514,682,865	0.0%	-129,793
<b>Total Liabilities</b>	2,270,295,586	2,370,343,137	4.4%	100,047,551
<b>Current Liabilities</b>	963,724,361	1,157,679,227	20.1%	193,954,866
Suppliers	345,923,604	309,785,052	-10.4%	-36,138,552
Short-term Bank Loans	-	-	0.0%	-
Short-term securities Loans	19,324,820	19,028,334	N/A	-296,486
Accrued interest and commission	-	-	N/A	-
Income tax payable	188,413,089	257,755,979	36.8%	69,342,890
Other Current Liabilities	322,354,634	479,012,041	48.6%	156,657,407
Short-term lease liability	87,708,213	92,097,821	5.0%	4,389,608
<b>Long-term Liabilities</b>	1,233,096,155	1,212,663,910	-1.7%	-20,432,245
Bank Loans	-	-	0.0%	-
Accrued Interest	989,725,252	990,828,238	N/A	1,102,986
Other Credits	37,135,499	38,548,542	3.8%	1,413,043
Long-term lease liability	206,235,404	183,287,131	-11.1%	-22,948,273
Deferred Income Taxes	73,475,070	-	N/A	-73,475,070
Other Liabilities	-	-	N/A	-
<b>Stockholders Equity</b>	4,008,865,290	4,297,406,107	7.2%	288,540,817
<b>Non-Controlling Interest</b>	983,775	992,691	0.9%	8,916
<b>Equity attributable to Equity Holders of the Company</b>	4,007,881,515	4,296,413,416	7.2%	288,531,901
Paid-in Capital Stock	517,873,932	517,873,932	0.0%	-
Premium in Share Placement	121,280,931	121,280,931	0.0%	-
Contributions for Future Capital Increases	124,628	124,628	0.0%	-
Retained earnings	2,816,774,577	3,205,811,603	13.8%	389,037,026
Reserve for Share Buyback Program	2,975,667	2,975,667	0.0%	-
Income of the year	558,827,822	458,288,263	-18.0%	-100,539,560
<b>Other Comprehensive Income</b>	-9,976,043	-9,941,609	-0.3%	34,434
<b>Total Liabilities and Shareholders Equity</b>	6,279,160,877	6,667,749,244	6.2%	388,588,368

Amounts in accordance with IFRS



## Financial Statements (unaudited) (amounts in MXN)

Médica Sur, S.A.B. de C.V.

### Income Statements of the second quarter of 2020 and 2021

	<u>2Q20</u>	<u>2Q21</u>	<u>Change % YoY</u>	<u>Change \$ YoY</u>
<b>Revenues</b>	<b>837,942,601</b>	<b>1,389,677,860</b>	<b>65.8%</b>	<b>551,735,259</b>
Cost of Sales	-593,101,407	-853,919,373	44.0%	-260,817,966
<b>Gross Profit</b>	<b>244,841,194</b>	<b>535,758,487</b>	<b>118.8%</b>	<b>290,917,293</b>
Selling and Administrative Expenses	-158,278,055	-221,763,662	40.1%	-63,485,606
Other Operating Expenses	3,258,214	-14,439,470	-543.2%	-17,697,684
<b>Operating Income</b>	<b>89,821,353</b>	<b>299,555,355</b>	<b>233.5%</b>	<b>209,734,002</b>
Foreign Exchange Gain (loss)	54,560	-3,303,755	-6155.3%	-3,358,315
Interest Expense	-38,048,602	-27,109,519	-28.8%	10,939,083
Interest Income	4,538,465	5,945,615	31.0%	1,407,150
<b>Income before Taxes</b>	<b>56,365,776</b>	<b>275,087,696</b>	<b>388.0%</b>	<b>218,721,920</b>
Income Tax Expense	-12,318,586	-83,714,703	579.6%	-71,396,117
<b>Continuous Operations Profit (loss)</b>	<b>44,047,190</b>	<b>191,372,993</b>	<b>334.5%</b>	<b>147,325,803</b>
Discontinued Operations Loss	-	-	-	-
<b>Net Income</b>	<b>44,047,190</b>	<b>191,372,993</b>	<b>334.5%</b>	<b>147,325,803</b>
Non-Controlling Income	-12,061	-37,940	214.6%	-25,879
<b>Controlling Income</b>	<b>44,035,128</b>	<b>191,335,052</b>	<b>334.5%</b>	<b>147,299,924</b>

Amounts in accordance with IFRS

## Financial Statements (unaudited) (amounts in MXN)

Médica Sur, S.A.B. de C.V.

Income statements for the first six months ended June 2020 and 2021

	<u>2020</u>	<u>2021</u>	<u>Change % YoY</u>	<u>Change \$ YoY</u>
<b>Revenues</b>	<b>1,764,848,029</b>	<b>2,817,222,057</b>	<b>59.6%</b>	<b>1,052,374,027</b>
Cost of Sales	-1,227,697,439	-1,687,737,375	37.5%	-460,039,935
<b>Gross Profit</b>	<b>537,150,590</b>	<b>1,129,484,682</b>	<b>110.3%</b>	<b>592,334,092</b>
Selling and Administrative Expenses	-330,901,508	-421,271,495	27.3%	-90,369,987
Other Operating Expenses	-7,380,785	-10,397,121	40.9%	-3,016,335
<b>Operating Income</b>	<b>198,868,297</b>	<b>697,816,067</b>	<b>250.9%</b>	<b>498,947,770</b>
Foreign Exchange Gain (loss)	2,837,045	-122,162	n.a.	-2,959,207
Interest Expense	-79,117,945	-53,318,370	-32.6%	25,799,575
Interest Income	6,789,158	11,470,194	68.9%	4,681,036
<b>Income before Taxes</b>	<b>129,376,555</b>	<b>655,845,729</b>	<b>406.9%</b>	<b>526,469,174</b>
Income Tax Expense	-35,654,094	-197,548,551	454.1%	-161,894,457
<b>Continuous Operations Profit (loss)</b>	<b>93,722,461</b>	<b>458,297,177</b>	<b>389.0%</b>	<b>364,574,716</b>
Discontinued Operations Loss	-	-	0.0%	0
<b>Net Income</b>	<b>93,722,461</b>	<b>458,297,177</b>	<b>389.0%</b>	<b>364,574,716</b>
Non-Controlling Income	-18,691	-8,915	-52.3%	9,776
<b>Controlling Income</b>	<b>93,703,770</b>	<b>458,288,263</b>	<b>389.1%</b>	<b>364,584,493</b>

All the financial information presented in this report was prepared in accordance with the International Financial Reporting Standards (IFRS)

## Coverage by Analysts

In accordance with the provisions of the internal regulations of the Mexican Stock Exchange (BMV by its initials in Spanish) set forth in article 4.033.01, section VIII, regarding maintenance requirements, we inform that the Brokerage House that provides analysis coverage to our securities is *Grupo Bursátil Mexicano S.A. de C.V., Casa de Bolsa*, and *Miranda Global Research* as an independent analyst.

## About MEDICA

MEDICA, S.A.B. de C.V. (BMV ticker symbols: MEDICAB and MEDICA 20) is a hospital operator and an integrated provider of healthcare and related services, provided through hospitals and laboratories. MEDICA relies on a group of physicians, medical professionals, nurses, administration and hospital operations aimed at offering a medical service of excellence with human approach guided by a strict code of ethics and supported by medical equipment and infrastructure with state-of-the-art technology.

## EBITDA\*

EBITDA is an indicator utilized in the financial analysis of the Company that is not recognized in the IFRS, but that is calculated based on the numbers derived from the Company's financial statements. We calculate EBITDA as the operations revenue plus the depreciation and amortization.

For the 2020 and 2021 numbers, the EBITDA includes the effects of the IFRS 16 leases accounting standard.

EBITDA is not a financial indicator under IFRS, nor is it an indicator of liquidity or performance. We consider that EBITDA can be useful to facilitate comparisons of operating performance between periods on a combined basis, but other issuers may calculate these metrics differently.

EBITDA must not be interpreted as an alternative to (i) Net Income as an indicator of the Company's operating performance, nor to (ii) the cash flow from operating activities as a measure of the Company's liquidity.

## Forward-Looking Statements

This report contains forward-looking statements. Such statements include, but are not limited to: (i) statements regarding our financial condition and operating results; (ii) statements regarding our plans, objectives, or targets, including statements with respect to our activities; and (iii) statements regarding the underlying assumptions on which those statements are based. Forward-looking statements contain words such as "intends," "anticipates," "considers," "estimates," "expects," "foresees," "plans," "predicts," "seeks," "could," "should," "possible," "guideline," and other similar terms, whether in first or third person. However, these are not the only terms used to identify these statements. By their very nature, forward-looking statements involve risks and uncertainties of both a general and a specific nature, including the risk that such predictions, forecasts, projection and other forward-looking statement will not be fulfilled. Investors are cautioned that there are many important factors that may cause actual results to differ materially from those expressed in the plans, objectives, expectations, estimates and statements, both expressed and implied, contained in the forwards-looking statements. The information related to future performance contained in this press release must be read jointly with the risks included in the "Risk Factors" section submitted to the National Banking and Securities Commission (CNBV).



**MEDICAB**

### CONTACT

Investor Relations: **Arely Gutiérrez**

Ph: 52(55) 5424 7200 Ext. 3425: [agutierrezg@medicasur.org.mx](mailto:agutierrezg@medicasur.org.mx)

Visit the Investor Relations site: <https://inversionistas.medicasur.com.mx/>